114.23
price up icon1.06%   1.20
after-market Dopo l'orario di chiusura: 114.28 0.05 +0.04%
loading

Gilead Sciences Inc Borsa (GILD) Ultime notizie

pulisher
03:20 AM

NY Judge Faces Recusal Request Over Gilead Stock Holdings - Law360

03:20 AM
pulisher
09:30 AM

AbbVie, Gilead and GSK back World Hepatitis Day, seeking to tackle stigma to drive elimination - Fierce Pharma

09:30 AM
pulisher
08:16 AM

Gilead price collects profitsForecast today29-07-2025 - Economies.com

08:16 AM
pulisher
07:58 AM

Integrase Inhibitors Market Growth and Future Scope 2025-2032 | - openPR.com

07:58 AM
pulisher
01:15 AM

Order Flow Trends Show Accumulation in Gilead Sciences Inc.Long Hold Safe Return Strategy Reviewed - metal.it

01:15 AM
pulisher
Jul 28, 2025

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

Why Gilead Sciences Stock Slipped Today - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

Gilead down as analysts see RFK Jr. preventative task force action negatively - Seeking Alpha

Jul 28, 2025
pulisher
Jul 28, 2025

Gilead Sciences stock falls amid reports of preventive health panel dismissal - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive - Stocktwits

Jul 28, 2025
pulisher
Jul 28, 2025

Is Gilead Sciences Inc. stock overvalued or undervaluedConsistent double returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Gilead Sciences Earns Membership In 95-Plus Composite Rating Club - Investor's Business Daily

Jul 28, 2025
pulisher
Jul 28, 2025

TD Cowen Remains Bullish on Gilead Sciences (GILD) - Insider Monkey

Jul 28, 2025
pulisher
Jul 28, 2025

Citi Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey

Jul 28, 2025
pulisher
Jul 27, 2025

What is Gilead Sciences Inc. company’s growth strategyFree Predictions - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire

Jul 27, 2025
pulisher
Jul 27, 2025

Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet? - simplywall.st

Jul 27, 2025
pulisher
Jul 27, 2025

Lenacapavir: After FDA approval, HIV pre-exposure prophylaxis injectable moving closer to EU approval - The Hindu

Jul 27, 2025
pulisher
Jul 26, 2025

Gilead Sciences Stock Surges Amid Promising Trials - TipRanks

Jul 26, 2025
pulisher
Jul 26, 2025

10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey

Jul 26, 2025
pulisher
Jul 25, 2025

European Medicines Agency Recommends Lenacapavir (Yeztugo) Injectable PrEP for HIV Prevention - Contagion Live

Jul 25, 2025
pulisher
Jul 25, 2025

Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Why Gilead Sciences Stock Just Popped - The Motley Fool

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences’ Latest Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three - insights.citeline.com

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales - Benzinga

Jul 25, 2025
pulisher
Jul 25, 2025

EU regulator backs Gilead's twice-yearly injection for HIV prevention - Reuters

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead upgraded to Buy at Needham on new HIV drug - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences (GILD) Gains Upgrade Amid Promising HIV Drug Outlook - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead stock upgraded at Needham on new HIV drug (GILD:NASDAQ) - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Gilead Sciences Inc. stockFree Stock Market Beginners Guide - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Analyst recommendations: Thermo Fisher Scientific, Intel, Honeywell International, Union Pacific, Gilead Sciences... - MarketScreener

Jul 25, 2025
pulisher
Jul 25, 2025

This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga

Jul 25, 2025
pulisher
Jul 25, 2025

EU regulator backs Gilead’s twice-yearly injection for HIV prevention - PharmaLive

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet - Stocktwits

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead wins EU backing for twice-yearly HIV PrEP therapy - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences’ Yeztugo: A Promising Growth Driver in the HIV PrEP Market with Undervalued Potential - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention - BioSpace

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead receives positive EU opinion for twice-yearly HIV prevention drug - StreetInsider

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention - Investing.com

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention By Investing.com - Investing.com Nigeria

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences and the Breakthrough Approval of Lenacapavir for HIV PrEP: A New Era in Global Health and Market Leadership - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Receives Positive Chmp Opinions Under Accelerated Review From European Medicines Agency For Twice-Yearly Lenacapavir For HIV Prevention - vih.org

Jul 25, 2025
pulisher
Jul 25, 2025

Is Gilead Sciences Inc. a good long term investmentMarket-leading profit generation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Gilead Sciences Inc. stock priceAccelerated wealth expansion - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Is Gilead Sciences Inc. stock a growth or value playTremendous gains - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - BioSpace

Jul 24, 2025
pulisher
Jul 24, 2025

Gilead and Arcus Biosciences’ Promising Lung Cancer Study: Market Implications - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Gilead Sciences Advances HIV Prevention with New Clinical Study - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Looking Back to the Future: Gilead’s Long-Standing Commitment To Help End the HIV Epidemic - CSRwire

Jul 24, 2025
pulisher
Jul 23, 2025

Attorney General Jeff Jackson Secures Over $200 Million from Gilead Sciences for Paying Kickbacks to Doctors - NCDOJ (.gov)

Jul 23, 2025
pulisher
Jul 23, 2025

AG Jackson announces major settlement with Gilead Sciences over kickbacks - WPDE

Jul 23, 2025
pulisher
Jul 23, 2025

Gilead Sciences, Omnicom Group, and QuinStreet Shares Skyrocket, What You Need To Know - TradingView

Jul 23, 2025
pulisher
Jul 23, 2025

Bridging the Gap: Gilead’s Work to Help End the HIV Epidemic - The Hollywood Reporter

Jul 23, 2025
pulisher
Jul 23, 2025

Looking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic - ACCESS Newswire

Jul 23, 2025
pulisher
Jul 23, 2025

What to Expect From Gilead Sciences’ Q2 2025 Earnings Report - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

What To Expect From Gilead Sciences’ Q2 2025 Earnings Report - Barchart.com

Jul 23, 2025
pulisher
Jul 22, 2025

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Lobbying Update: $1,700,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Gilead and Arcus Biosciences’ Promising Phase 3 Lung Cancer Study Update - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda - insights.citeline.com

Jul 22, 2025
drug_manufacturers_general PFE
$24.30
price down icon 0.04%
drug_manufacturers_general SNY
$49.35
price down icon 0.26%
$303.56
price up icon 0.75%
drug_manufacturers_general NVO
$53.94
price down icon 21.83%
drug_manufacturers_general MRK
$82.63
price down icon 1.70%
Capitalizzazione:     |  Volume (24 ore):